TY - JOUR T1 - In patients with cancer and venous thromboembolism (VTE), enoxaparin was as effective as warfarin for VTE prophylaxis and reduced fatal haemorrhage JF - Evidence Based Medicine JO - Evid Based Med SP - 85 LP - 85 DO - 10.1136/ebm.8.3.85 VL - 8 IS - 3 A2 - , Y1 - 2003/05/01 UR - http://ebm.bmj.com/content/8/3/85.abstract N2 - (2002) Arch Intern Med 162, 1729. Meyer G, Marjanovic Z, Valcke J, et al.. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study.. ;. :. –35.OpenUrlCrossRefPubMedWeb of Science
 
 QUESTION: In patients with cancer and venous thromboembolism (VTE), is a fixed dose of subcutaneous low molecular weight (LMW) heparin better than oral warfarin for secondary prophylaxis of VTE? Randomised {allocation concealed*}†, blinded {outcome assessors and data analysts}†,* controlled trial with primary follow up to 3 months. 25 centres in France. 146 patients >18 years of age (mean age 66 y, 55% women) with cancer of any type and deep venous thrombosis and/or pulmonary embolism. Exclusion criteria were previous heparin induced thrombocytopenia, allergy to iodine, pregnancy, fibrinolytic treatment within 3 days, oral anticoagulant use for >5 days, treatment with full dose heparin for this episode of VTE, major pulmonary embolism with shock, life expectancy <3 months, contraindication to anticoagulants, severe hepatic failure, planned major surgery or … ER -